Want to see ACXP full AI Analyst Report?
ACXP Stock Chart & Stats
$1.42
$0.01(0.70%)
At close: 4:00 PM EDT
$1.42
$0.01(0.70%)
Day’s Range― - ―
52-Week Range$1.33 - $8.34
Previous CloseN/A
Volume25.68K
Average Volume (3M)1.14M
Market Cap
$5.97M
Enterprise Value-$6.81M
Total Cash (Recent Filing)$9.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Aug 14, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.91
Shares Outstanding4,297,738
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.71
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.91
Forecast
1Y Price Target
$17.00Price Target Upside1097.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyRobust Phase II results (≈96% cure, no 1-month recurrences) provide a durable signal of clinical activity and recurrence prevention. This strengthens the case for registrational development, supports regulatory meetings, and can improve trial recruitment and partner interest if replicated in larger trials.
Regulatory PathwayThe FDA's single‑trial guidance and potential LPAD pathway materially lower structural regulatory hurdles versus a two‑trial standard. That can shorten development timelines and reduce required patient numbers and cost, improving the feasibility of demonstrating efficacy with one pivotal program.
Balance Sheet (No Debt)No debt reduces financial risk and preserves strategic optionality for partnerships, licensing, or staged financings. Over 2–6 months this grants management flexibility in structuring non‑dilutive or less dilutive funding and limits fixed obligations that could pressure operations during development.
Bears Say
Cash RunwayCash of ~$9.3M is insufficient to fund a registrational Phase III program, creating a durable financing constraint. The company will likely need additional capital or partnerships before late‑stage trials, increasing dilution risk, potential delays, or dependence on counterparty terms that affect strategic control.
Pre‑Revenue Cash BurnBeing pre‑revenue and cash‑burning means the business lacks internal funding sources and depends on external capital. Even with narrowing losses, sustained negative operating and free cash flow create structural funding risk that can influence program pacing, partner negotiations, and shareholder dilution over the medium term.
Early‑Stage Data Size & Design RiskThe initial rCDI pilot (20 patients, open‑label) provides limited confirmatory evidence; regulators and payers typically require larger randomized active‑controlled trials. This structural clinical risk means positive Phase II signals must be replicated in costly, time‑consuming trials to secure approval and commercial acceptance.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $1.32 and its highest was $8.34 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $5.97M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Aug 14, 2026 which is in 13 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$1.2 by $0.58.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -0.38.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 4,297,738 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, beating expectations of -$1.2. Following the earnings report the stock price went down -5.963%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed materially positive clinical and IP progress: compelling Phase II efficacy with no observed recurrence among cured patients, initiation of an rCDI pilot, favorable FDA guidance that could reduce pivotal trial requirements, strengthened patent protection, supportive preclinical data, and recent financings that improved cash. Key negatives are the modest cash position relative to Phase III needs, small-scale early rCDI data requiring larger controlled trials, and remaining regulatory and design uncertainties. On balance, the positive clinical, regulatory and IP developments outweigh the operational and financing risks disclosed.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$17.00
▲(1097.18% Upside)
Technical Analysis
Ownership Overview
55.41%
Insiders
1.06% Mutual Funds
0.34% Other Institutional Investors
42.46% Public Companies and
Individual Investors